Genetic and Clinical Predictors of Left Atrial Thrombus: A Single Center Case-Control Study

Standard

Genetic and Clinical Predictors of Left Atrial Thrombus: A Single Center Case-Control Study. / Springer, Adrian; Schleberger, Ruben; Oyen, Florian; Hoffmann, Boris A; Willems, Stephan; Meyer, Christian; Langer, Florian; Schnabel, Renate B; Kirchhof, Paulus; Schneppenheim, Reinhard; Lemoine, Marc D.

In: CLIN APPL THROMB-HEM, Vol. 27, 30.06.2021, p. 10760296211021171.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

APA

Vancouver

Springer A, Schleberger R, Oyen F, Hoffmann BA, Willems S, Meyer C et al. Genetic and Clinical Predictors of Left Atrial Thrombus: A Single Center Case-Control Study. CLIN APPL THROMB-HEM. 2021 Jun 30;27:10760296211021171. https://doi.org/10.1177/10760296211021171

Bibtex

@article{7cdb399baf3b49f6853cebf9787ed026,
title = "Genetic and Clinical Predictors of Left Atrial Thrombus: A Single Center Case-Control Study",
abstract = "Left atrial (LA) thrombus formation is the presumed origin of thromboembolic complications in patients with atrial fibrillation (AF). Beyond clinical risk factors, the factors causing formation of LA thrombi are not well known. In this case-control study, we analyzed clinical characteristics and genetic thrombophilia markers (factor V Leiden (FVL), prothrombin G20210A (FIIV), Tyr2561 variant of von Willebrand factor (VWF-V)) in 42 patients with AF and LA thrombus (LAT) and in 68 control patients with AF without LAT (CTR). Patients with LAT had more clinical conditions predisposing to stroke (mean CHA2DS2-VASc-score 3.4 ± 1.5 vs. 1.9 ± 1.4; P < 0.001), a higher LA volume (96 ± 32 vs. 76 ± 21 ml, P = 0.002) and lower LA appendage emptying velocity (0.21 ± 0.11vs. 0.43 ± 0.19 m/s, P < 0.001). Prevalence of FVL, FIIV and VWF-V mutations was not different, but in the subgroup of patients <65 years (y) there was a tendency for a higher incidence of VWF-V with a prevalence of 27% (LAT <65 y) vs. 7% (CTR <65 y, P = 0.066). These findings warrant further investigation of the VWF-V as a risk factor for LA thrombogenesis in younger patients.",
author = "Adrian Springer and Ruben Schleberger and Florian Oyen and Hoffmann, {Boris A} and Stephan Willems and Christian Meyer and Florian Langer and Schnabel, {Renate B} and Paulus Kirchhof and Reinhard Schneppenheim and Lemoine, {Marc D}",
year = "2021",
month = jun,
day = "30",
doi = "10.1177/10760296211021171",
language = "English",
volume = "27",
pages = "10760296211021171",
journal = "CLIN APPL THROMB-HEM",
issn = "1076-0296",
publisher = "SAGE Publications",

}

RIS

TY - JOUR

T1 - Genetic and Clinical Predictors of Left Atrial Thrombus: A Single Center Case-Control Study

AU - Springer, Adrian

AU - Schleberger, Ruben

AU - Oyen, Florian

AU - Hoffmann, Boris A

AU - Willems, Stephan

AU - Meyer, Christian

AU - Langer, Florian

AU - Schnabel, Renate B

AU - Kirchhof, Paulus

AU - Schneppenheim, Reinhard

AU - Lemoine, Marc D

PY - 2021/6/30

Y1 - 2021/6/30

N2 - Left atrial (LA) thrombus formation is the presumed origin of thromboembolic complications in patients with atrial fibrillation (AF). Beyond clinical risk factors, the factors causing formation of LA thrombi are not well known. In this case-control study, we analyzed clinical characteristics and genetic thrombophilia markers (factor V Leiden (FVL), prothrombin G20210A (FIIV), Tyr2561 variant of von Willebrand factor (VWF-V)) in 42 patients with AF and LA thrombus (LAT) and in 68 control patients with AF without LAT (CTR). Patients with LAT had more clinical conditions predisposing to stroke (mean CHA2DS2-VASc-score 3.4 ± 1.5 vs. 1.9 ± 1.4; P < 0.001), a higher LA volume (96 ± 32 vs. 76 ± 21 ml, P = 0.002) and lower LA appendage emptying velocity (0.21 ± 0.11vs. 0.43 ± 0.19 m/s, P < 0.001). Prevalence of FVL, FIIV and VWF-V mutations was not different, but in the subgroup of patients <65 years (y) there was a tendency for a higher incidence of VWF-V with a prevalence of 27% (LAT <65 y) vs. 7% (CTR <65 y, P = 0.066). These findings warrant further investigation of the VWF-V as a risk factor for LA thrombogenesis in younger patients.

AB - Left atrial (LA) thrombus formation is the presumed origin of thromboembolic complications in patients with atrial fibrillation (AF). Beyond clinical risk factors, the factors causing formation of LA thrombi are not well known. In this case-control study, we analyzed clinical characteristics and genetic thrombophilia markers (factor V Leiden (FVL), prothrombin G20210A (FIIV), Tyr2561 variant of von Willebrand factor (VWF-V)) in 42 patients with AF and LA thrombus (LAT) and in 68 control patients with AF without LAT (CTR). Patients with LAT had more clinical conditions predisposing to stroke (mean CHA2DS2-VASc-score 3.4 ± 1.5 vs. 1.9 ± 1.4; P < 0.001), a higher LA volume (96 ± 32 vs. 76 ± 21 ml, P = 0.002) and lower LA appendage emptying velocity (0.21 ± 0.11vs. 0.43 ± 0.19 m/s, P < 0.001). Prevalence of FVL, FIIV and VWF-V mutations was not different, but in the subgroup of patients <65 years (y) there was a tendency for a higher incidence of VWF-V with a prevalence of 27% (LAT <65 y) vs. 7% (CTR <65 y, P = 0.066). These findings warrant further investigation of the VWF-V as a risk factor for LA thrombogenesis in younger patients.

U2 - 10.1177/10760296211021171

DO - 10.1177/10760296211021171

M3 - SCORING: Journal article

C2 - 34184557

VL - 27

SP - 10760296211021171

JO - CLIN APPL THROMB-HEM

JF - CLIN APPL THROMB-HEM

SN - 1076-0296

ER -